What is the purpose of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial?
The purpose of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial is to investigate the efficacy of apixaban in reducing the risk of thromboembolic events in patients with device-detected sub-clinical atrial fibrillation.